Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia's (ASX: ACL) subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101^st Annual Meeting in Washington, DC. The data demonstrates the ability of the Company's HyACT tumour targeting technology to dramatically enhance the killing of cancer stem cells. These cells are highly resistant to treatment with chemotherapeutic drugs and are believed to be responsible for treatment failure and disease recurrence.

“These data provide additional excitement around the technology as we prepare to start the pivotal Phase III study of HA-Irinotecan in colorectal cancer.”

Two posters were presented today at the 'Cancer Stem Cell Therapeutics 2' session from 2:00-5:00pm EDT in Exhibit Hall A-C entitled,

Poster #4278: HA-Irinotecan targeting of activated CD44 is an effective therapy for the eradication of putative colon cancer stem cells

Poster #4293: Evaluation of activated CD44 as a biological target in the eradication of breast cancer stem cells

In new data presented today by Professor Tracey Brown, Alchemia's Vice President of Preclinical Research, the HyACT formulation of doxorubicin (HA-Doxorubicin) has been shown to be up to forty times more potent than doxorubicin alone in killing putative breast cancer stem cells. Similarly, in human colorectal cancer cells, HyACT formulations of the drug irinotecan (HA-Irinotecan) showed up to a fifty fold increase in potency against stem cell like populations.

Despite advances in the treatment of cancer with new chemotherapeutic agents and targeted therapies, many patients develop tumours that are resistant to treatment, resulting in treatment failure. In recent years, attention has focused on the role of a sub-population of cells, referred to as 'cancer stem cells', which are highly resistant to treatment. One of the markers used to define this difficult to eradicate cell population is CD44, which is specifically targeted by Alchemia's HyACT technology.

"In previous research we have clearly established that reformulation of cancer drugs with HyACT enhances the ability of that drug to kill cells expressing the receptor CD44," said Professor Tracey Brown. "It is increasingly accepted that cancer stem cells from a majority of solid tumours express high levels of activated CD44. Our research presented today confirms that targeting of drugs to that receptor with HyACT may help to eradicate this otherwise difficult to treat population of cells. Indeed, it may explain the significant increases in efficacy that we have seen in previously reported Phase 2 clinical studies of HA-Irinotecan in colorectal cancer and preclinical data from models of several different cancer types."

"The role of cancer stem cells in the genesis and progression of the disease is receiving intense scrutiny in the research and clinical communities," said Pete Smith, CEO of Alchemia. "These data provide additional excitement around the technology as we prepare to start the pivotal Phase III study of HA-Irinotecan in colorectal cancer."

The posters presented at today's session at AACR are now available to view on Alchemia's website: www.alchemia.com.au/irm/content/investor_presentations.html

Source Alchemia Limited

www.alchemia.com.au